- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
5
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
5 companies
Akeso
Market Cap: HK$73.6b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$81.95
7D
-5.8%
1Y
97.9%
RemeGen
Market Cap: HK$33.3b
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
9995
HK$47.30
7D
2.0%
1Y
85.9%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$73.9b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$331.80
7D
8.1%
1Y
78.5%
Genscript Biotech
Market Cap: HK$29.3b
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
1548
HK$13.44
7D
4.3%
1Y
46.9%
Innovent Biologics
Market Cap: HK$119.3b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.
1801
HK$72.30
7D
16.4%
1Y
102.2%